Management of vaccine-induced thrombosis and thrombocytopenia, RCS

There are increasing reports of a rare adverse event of thrombosis and thrombocytopenia following the first dose of the AstraZeneca COVID-19 vaccine, a syndrome labelled vaccine-induced thrombotic thrombocytopenia syndrome (VITT). The colleges and surgical specialty associations have produced guidance on the features and management of VITT, taking into account vascular, gastrointestinal and neurosurgical considerations.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news